Drugs for the treatment of pulmonary arterial hypertension
Status Discontinued
Decision Selected
Process MTA
Referral date 01 April 2005
Topic area
  • Cardiovascular
  • Therapeutic procedures

Provisional Schedule

Consultation on draft scope by stakeholders: October 2006
Closing date for invited submissions / evidence submission: 10 May 2007
Final scope published: January 2007
1st appraisal committee meeting: 03 October 2007
2nd appraisal committee meeting: 05 February 2008
3rd appraisal committee meeting: 03 April 2008

Project Team

Assessment Group / Evidence Review Group: West Midlands Health Technology Assessment Collaboration
Communications manager: Kristin O'Leary
Executive Lead: Peter Littlejohns
Project manager: Jeremy Powell
Technical Lead: Helen Knight


Manufacturers / Sponsors Actelion Pharmaceuticals UK Ltd (bosentan)
  Encysive pharmaceuticals UK Ltd (sitaxsentan)
  GlaxoSmithKline (epoprostenol)
  Pfizer Ltd (Sildenafil citrate)
  Bayer Schering Pharma (iloprost)
Others Department of Health
  London specialised commissioning Group
  West Midlands Specialised Commissioning Team
  Welsh Assembly Government
Patient / Carer Groups Pulmonary Hypertension Association UK
  Raynaud's and Scleroderma Association
  Scleroderma Society
Professional Groups British Cardiovascular Society
  British Heart Foundation
  British Society for Rheumatology
  British Thoracic Society
  National Pulmonary Hypertension Service
  Royal College of Nursing
  Royal College of Physicians
Assessment Team National Coordinating Centre for Health Technology Assessment
  West Midlands Health Technology Assessment Collaboration
Comparator Manufacturers None
General Department of Health, Social Services and Public Safety for Northern Ireland
  Medicines and Healthcare products Regulatory Agency (MHRA)
  NHS Quality Improvement Scotland
Research Groups British Society for Cardiovascular Research


Key events during the development of the guidance:

Date Update
27 May 2005 Topic summary published.
17 October 2007 Timelines extended to accommodate additional analysis requested by the committee. Second committee meeting rescheduled.
09 November 2007 Request to stakeholders seeking additional observational or registry data on the survival benefit provided by the drugs that are subject to this appraisal.
28 October 2008 Consultees and commentators were invited to comment on a revised remit, scope and provisional matrix
25 November 2008 Closing date for comment on draft scope, remit and matrix
30 March 2009 The appraisal was removed from the NICE work programme

For further information on our processes and methods, please see our CHTE processes and methods manual